Scott Gunther - Catalent President
President
Mr. Scott Gunther is Senior Vice President Quality Regulatory Affairs of the Company. Mr. Gunther was named our Senior Vice President of Quality Regulatory Affairs in May 2017. Mr. Gunther joined us in 2012 as Vice President, Quality and most recently oversaw the quality function for the United States sites in our Drug Delivery Solutions business unit. Previously, he concurrently served as an interim Vice President of Product Development for our Drug Delivery Solutions business unit. Prior to joining us, Mr. Gunther spent 22 years with BristolMyersSquibb in various roles of increasing responsibility. In his last role at Bristol, he held the position of Executive Director Quality Operations Americas, where he was responsible for quality operations at its manufacturing sites in the U.S., Puerto Rico, and Latin America since 2017.
| Age | 52 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Scott Gunther Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Gunther against Catalent stock is an integral part of due diligence when investing in Catalent. Scott Gunther insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Gunther over a year ago Disposition of 387 shares by Scott Gunther of Catalent at 56.2 subject to Rule 16b-3 |
Catalent Management Efficiency
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| David Montecalvo | West Pharmaceutical Services | 54 | |
| Ilan Daskal | Bio Rad Laboratories | 58 | |
| Bhavik Patel | IQVIA Holdings | 45 | |
| Cameron Hicks | Teleflex Incorporated | 60 | |
| Rob Kotchie | IQVIA Holdings | N/A | |
| Richard III | IQVIA Holdings | 62 | |
| Jon Resnick | IQVIA Holdings | N/A | |
| Giovanni Magni | Bio Rad Laboratories | 63 | |
| James Leyden | Teleflex Incorporated | 52 | |
| David Smith | Charles River Laboratories | 58 | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Eric Sherbet | IQVIA Holdings | 60 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Ronald Bruehlman | IQVIA Holdings | 64 | |
| William Barbo | Charles River Laboratories | 64 | |
| Roger Graham | Teleflex Incorporated | N/A | |
| Ronald Hutton | Bio Rad Laboratories | 62 | |
| Timothy Ernst | Bio Rad Laboratories | 64 | |
| Praneet Mehrotra | Teleflex Incorporated | N/A | |
| Annette Favorite | West Pharmaceutical Services | 60 | |
| Cynthia Verst | IQVIA Holdings | N/A | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 16.13 B | |||
| Shares Outstanding | 181.51 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 14.74 M | |||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |